These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
379 related items for PubMed ID: 15300236
1. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M. Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236 [Abstract] [Full Text] [Related]
2. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R. Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549 [Abstract] [Full Text] [Related]
7. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, Fenk R, Hinke A, Haas R, Kobbe G. Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769 [Abstract] [Full Text] [Related]
8. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH). Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992 [Abstract] [Full Text] [Related]
11. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model]. Huang H, Zheng W, Lin M, Fu J, Zhang R. Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455 [Abstract] [Full Text] [Related]
12. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843 [Abstract] [Full Text] [Related]
19. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. Yerushalmi R, Shem-Tov N, Danylesko I, Shouval R, Nagler A, Shimoni A. Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467 [Abstract] [Full Text] [Related]
20. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P, Li QC, Zhang ZM, Liu KY, Huang XJ. J Hematol Oncol; 2014 Aug 21; 7():59. PubMed ID: 25139202 [Abstract] [Full Text] [Related] Page: [Next] [New Search]